

Notice of Annual Meeting of Shareholders

Notice is hereby given that the Annual Meeting of shareholders of AFT Pharmaceuticals Limited (AFT or the Company) will be held at the Milford Cruising Club, 24 Craig Road, Milford, Auckland, New Zealand, on **Friday, 31 July 2026 commencing at 10.30am** (New Zealand time).

Business

The business of the meeting will be:

- A. Chair's address
- B. Managing Director's address
- C. Resolutions: To consider, and if thought fit, pass the following ordinary resolutions:

- 1. Re-election of Marree Atkinson: That Marree Atkinson, who retires by rotation and is eligible for re-election, be re-elected as a director of the Company.
- 2. Auditor's remuneration: That the directors be authorised to fix the fees and expenses of the auditor for the ensuing year.

Refer to the explanatory notes for further details on these resolutions.

The Board recommends unanimously that you vote in favour of all resolutions.

- D. General Business: To consider such other business as may be properly raised at the meeting.

By Order of the AFT Pharmaceuticals Limited Board



David Flacks
Chair

02 July 2026

Resolution 1: Re-election of Marree Atkinson as a Director

Marree was appointed as an executive director by the shareholders of AFT on 4 September 2012 and was last re-elected in 2023. In accordance with the applicable NZX listing rules and the Company's constitution, Marree retires by rotation and being eligible, offers herself for re-election as a director of AFT at the meeting. The Board unanimously supports Marree's re-election and considers Marree to be a non-independent director as she is an executive officer and a discretionary beneficiary of the majority shareholder of AFT.

Resolution 2: Auditor's Remuneration

Deloitte is automatically reappointed auditor of the Company at the Annual Meeting pursuant to section 207T of the Companies Act 1993. The resolution sought is to authorise the directors to fix the remuneration of the auditor pursuant to section 207S of the Companies Act 1993.

Attendance at Meeting

All shareholders registered on the Company's share register at close of trading on Wednesday 29 July 2026 are entitled to attend and vote at the meeting.

Voting and Proxies

Voting at the meeting shall be by way of a poll of the Company's shareholders entitled to vote and voting.

A shareholder entitled to attend and vote at the meeting can appoint a proxy to attend and vote on that shareholder's behalf. A proxy need not be a shareholder. The Chair of the meeting may be appointed to act as proxy.

If the Chair of the meeting is appointed to act as proxy and is not directed how to vote, the Chair will vote in favour of all the resolutions.

If you do not name a person as your proxy but otherwise complete the proxy form in full or your named proxy does not attend the meeting, the Chair will act as your proxy and will only vote in accordance with your express direction.

A shareholder wishing to appoint a proxy can do so by visiting www.investorvote.co.nz. Shareholders will be required to enter the Control Number (available on your proxy form), their CSN/Holder Number and postcode or country of residence to complete the online appointment.

Alternatively, shareholders can appoint a proxy by completing the enclosed proxy form and returning it to Computershare Investor Services Limited by any of the methods specified on the proxy form.

The proxy form must be received no later than 10.30am on Wednesday 29 July 2026 (being 48 hours prior to the meeting).

Webcast

The Annual Meeting will be webcast live. To view and listen to the webcast, please visit [AFT 2026 Annual Meeting webcast](#)

<https://webcast.openbriefing.com/afp-agm-2026/>

Note that shareholders joining by webcast will not be able to vote at the meeting or ask questions. In order to vote you will need to appoint a proxy in accordance with the above instructions before 10.30am on Wednesday 29 July 2026.

If you have any questions you would like considered at the meeting, please send them to investor.relations@aftpharm.com in advance of the meeting.

More Information

If you have any questions, or for more information, please contact AFT's Company Secretary, at investor.relations@aftpharm.com